TAKANAWA PHARMACEUTICAL

Introduction

Our team initially started to work together in 2007 when working for Actavis, a leading global generic pharma company. Then in 2010 we established together Takanawa Pharma, an advisory with a focus on M&A in the generic pharma sector and partnering for new product development, especially in the area of oncology. Since 2014 we also started to register our own non-Japanese pharma products as Japan exclusive distributor. So now we both develop and invest in projects as well as advice cross border transactions and alliances between companies in Japan, EU and USA

TAKANAWA PHARMACEUTICAL EXPERTISE

  • Seasoned pharmaceutical industry specialists, with extensive global experience
  • Strong track record in pharmaceuticals, health care products and partnering
  • Strong network among the top management of the leading pharmaceutical companies in Japan
  • Strong connection with KOLs in oncology in Japan
  • Active participation in leading industry bodies such as Japanese Pharmaceutical Manufacturers Association and Japanese Pharma Licensing Association
  • Strong ties to governmental organizations responsible for registration and monitoring of pharma related production and imports

TAKANAWA PHARMACEUTICAL SERVICES

  • Facilitate acquisition and investment opportunities
  • Develop and invest in projects from registration to market distribution with partners
  • Strategic advisory
  • Conduct market study
  • Introduce licensing-out/in opportunities in Japan and coordinate evaluations
  • Introduce Japanese alliance partners
  • Plan and manage clinical studies and organize PMDA consultation through our business partner JCRO
  • Investigate regulatory pathways and manage registration of medical device and pharmaceutical products through our partner PPG

Examples of transactions by Takanawa Team Members, in their prior positions

  • For Sanofi, coordinate evaluation and negotiate in-licensing of the global leading oncology product Camptothecin (irinotecan) from Yakult for the European market
  • For Sanofi, coordinate evaluation and negotiate in-licensing of G-CSF from Chugai for the European market, which led to the establishment of a JV between Sanofi and Chugai
  • For Yakult, negotiate in-licensing of G-CSF from Kyowa Hakko Kirin, for the Japanese market
  • For Sanofi, negotiate out-licensing of the global leading oncology product docetaxel to Chugai for the Japanese market
  • For Kyowa Hakko Kirin, negotiate the $475 m. acquisition of ProStrakan, a Scottish pharmaceutical company
  • For Kyowa Hakko Kirin, negotiate the $500 m. out-licensing of the humanized monoclonal antibody KW-0761
  • For Kyowa Hakko Kirin, project read preclinical studies of Vinorelbine , for lung and breast cancer, from Pierre Fabre
  • For Astellas, negotiate the acquisition of the co-promotion rights of the blockbuster hypertension product Micardis from Boehringer Ingelheim. Product peak sale was about $1 bn. and it was Astellas largest product in 2013
  • For Actavis, coordinate and facilitate a JV with Aska Pharmaceutical, a Takeda Group company
  • For Actavis, coordinate and facilitate the establishment of Actavis’ oncology business in Japan

Company registration

  • Takanawa Pharma is operated by the registered company Takanawa Japan K.K. (Takanawa Japan Co., Ltd) in Tokyo, Japan